Equitable access to newer antibiotics relies on commitments to strengthening health systems’ infrastructure and facilitating coherent evidence generation. Improved coordination among key stakeholders including government-private-global health actor partnerships, regulatory harmonisation and pooled procurement could significantly alleviate immediate challenges.

Prof Rathi Saravanan
Prof James Leong

Click here to read